Korean J Physiol Pharmacol.  2001 Oct;5(5):443-449.

THI 52 inhibits inducible nitric oxide synthase gene expression in RAW 264.7 cells and rat lung tissue by lipopolysaccharide

Affiliations
  • 1Department of Pharmacology, College of Medicine, Gyeongsang National University, Jinju, 660-751, South Korea. kcchang@nongae.gsnu.ac.kr

Abstract

Previously we reported that THI 52 inhibits tumor necrosis factor (TNF)-alpha mRNA expression in mouse peritoneal macrophages exposed to LPS plus IFN-gamma. In the present study, the effects of THI 52 on vascular reactivity ex vivo, and iNOS protein expression (rat lung) were investigated in LPS-treated rats. Treatment of THI 52 concentration-dependently reduced not only serum nitrite production but also the expression of iNOS protein in rat lung tissues. Thoracic aorta taken from LPS injected rat for 8 h ex vivo resulted in suppression of vasoconstrictor effects to phenylephrine (PE), which was restored by THI 52 (20 mg/kg) 30 min prior to LPS. When measured iNOS activity, treatment of THI 52 concentration-dependently reduced the enzyme activity in RAW 264.7 cells activated with LPS plus IFN-gamma. Likewise, iNOS activity was significantly reduced in lung tissues taken those rats that were injected THI 52 prior to LPS injection compared with LPS injection alone. These results strongly suggest that THI 52 can suppress iNOS gene expression induced by LPS, and restore the vascular contractility to PE. Thus, THI 52, a new synthetic isoquinoline alkaloid, may be beneficial in inflammatory disorders where production of NO is excessed by iNOS expression.


MeSH Terms

Animals
Aorta, Thoracic
Gene Expression*
Lung*
Macrophages, Peritoneal
Mice
Nitric Oxide Synthase Type II*
Phenylephrine
Rats*
RNA, Messenger
Tumor Necrosis Factor-alpha
Nitric Oxide Synthase Type II
Phenylephrine
RNA, Messenger
Tumor Necrosis Factor-alpha
Full Text Links
  • KJPP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr